Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

280 questions · 284 findings · 102 reviews

No studies found 14 · 4.9%GRADE not reported 9 · 3.2%Very low 138 · 48.6%Low 62 · 21.8%Moderate 58 · 20.4%High 3 · 1.1%

COGNITIVE BEHAVIOUR THERAPY + MOTIVATIONAL INTERVIEWING vs usual care

Lost to treatment · people with both severe mental illness and substance misuse

Cognitive behavioural therapy + motivational interviewing showed no clear difference in leaving the study early: Lost to treatment compared with standard care (low certainty).

1 finding from 1 review

Non‐integrated models of care ‐ Assertive community treatment only/Intensive case management/Specialised case management services vs usual care

Lost to treatment · people with both severe mental illness and substance misuse

It is very uncertain whether non‐integrated models of care ‐ Assertive community treatment… changes leaving the study early: Lost to treatment compared with standard care (very low certainty).

1 finding from 1 review

Pericyazine vs atypical antipsychotics

Leaving the study early for specific reasons · patients with schizophrenia

It is very uncertain whether pericyazine changes leaving the study early for specific reasons compared with atypical antipsychotic (very low certainty).

1 finding from 1 review

Pericyazine vs Typical antipsychotics

Leaving the study early for specific reasons · patients with schizophrenia

It is very uncertain whether pericyazine changes leaving the study early for specific reasons compared with typical antipsychotic (very low certainty).

1 finding from 1 review

Levomepromazine vs Typical antipsychotics

Leaving the study early ‐ long term ‐ lost to · patients with schizophrenia

Levomepromazine showed no clear difference in leaving the study early ‐ long term ‐ lost to compared with typical antipsychotics (moderate certainty).

1 finding from 1 review

Levomepromazine vs atypical antipsychotics

Leaving the study early ‐ short term ‐ lost to · patients with schizophrenia

Levomepromazine showed no clear difference in leaving the study early ‐ short term ‐ lost to compared with atypical antipsychotics (low certainty).

1 finding from 1 review

RISPERIDONE DEPOT vs QUETIAPINE

Leaving the study early · patients with schizophrenia

RISPERIDONE DEPOT probably leads to lower leaving the study early: Any reason ‐ long term compared with ORAL QUETIAPINE (moderate certainty).

1 finding from 1 review

RISPERIDONE DEPOT vs ARIPIPRAZOLE

Leaving the study early · patients with schizophrenia

It is very uncertain whether RISPERIDONE DEPOT changes leaving the study early: Any reason ‐ long term compared with ORAL ARIPIPRAZOLE (very low certainty).

1 finding from 1 review

RISPERIDONE DEPOT vs OLANZAPINE

Leaving the study early · patients with schizophrenia

RISPERIDONE DEPOT may leads to higher leaving the study early: Any reason ‐ long term compared with ORAL OLANZAPINE (low certainty).

1 finding from 1 review

ACUPUNCTURE added to LOW DOSE ANTIPSYCHOTICS vs STANDARD DOSE ANTIPSYCHOTICS

Behaviour: Leaving the study early (short‐term) · patients with schizophrenia

It is very uncertain whether ACUPUNCTURE added to LOW DOSE ANTIPSYCHOTICS changes behaviour: Leaving the study early (short‐term) compared with STANDARD DOSE ANTIPSYCHOTICS (very low certainty).

1 finding from 1 review

ACUPUNCTURE added to STANDARD DOSE ANTIPSYCHOTICS vs STANDARD DOSE ANTIPSYCHOTICS

Behaviour: Leaving the study early (short‐term) · patients with schizophrenia

It is very uncertain whether ACUPUNCTURE added to STANDARD DOSE ANTIPSYCHOTICS changes behaviour: Leaving the study early (short‐term) compared with STANDARD DOSE ANTIPSYCHOTICS (very low certainty).

1 finding from 1 review

Acupuncture vs TCM DRUG

Behaviour: Leaving the study early (short‐term) · patients with schizophrenia
1 finding from 1 review

RISPERIDONE DEPOT vs RISPERIDONE

Behaviour: Leaving the study early (short‐term) · patients with schizophrenia

RISPERIDONE DEPOT showed no clear difference in leaving the study early: Any reason ‐ short term compared with ORAL RISPERIDONE (moderate certainty).

1 finding from 1 review